Peptomyc
Hugo Thabussot is a PhD candidate and laboratory technician at Peptomyc since January 2020, with a solid foundation in biochemistry and molecular biology. Previously, Hugo completed a research trainee position at IRB Barcelona, contributing to the design and synthesis of photoswitchable peptides for biomedical applications. Prior to that, Hugo undertook research training at CNRS, focusing on the organic synthesis of a NADH analogue for electro-biochemistry applications. Hugo holds a Doctor of Philosophy degree from Universitat Autònoma de Barcelona, a Master's degree from Université Claude Bernard Lyon 1, a Bachelor's degree from Inland Norway University of Applied Sciences, and a DEUG from Université de Bourgogne.
This person is not in the org chart
This person is not in any teams
Peptomyc
Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.